

**PLAINTIFF'S
EXHIBIT
CAM-257**

**PROPOSED OUTLINE FOR TALC TECHNICAL PRESENTATION
AT THE FDA TALC SYMPOSIUM**

Presenter: Luzenac America Inc., the leading U.S. producer of industrial, cosmetic, pharmaceutical, and food grade talc products.

1. Market Overview

- a. U.S. sales (volumes) of cosmetic, food grade, and pharmaceutical grade talc products.
- b. Estimate of worldwide production and talc usage.
- c. Talc attributes; reasons for use.

2. Mineral Sources

- a. Tying in the desired attributes, show locations of major U.S. and foreign mines. Briefly discuss major features.
- b. Briefly discuss geology of sources. Likelihood of asbestos contamination in ores.

3. Manufacturing Processes

- a. Typical flotation circuit. Approx. quantity (percentage of market) of U.S. dusting powders produced by this process. Approx. quantity (percentage) of U.S. market for USP and FCC products produced by this process.
- b. Typical dry processing circuit. Approx. quantity (percentage) of US dusting powders, USP, and FCC products produced by this process.

4. Product Specifications

- a. CTFA, USP, FCC, and "customer" specifications (possibly including reference to FDA GMP's).
- b. Particle size data on actual dusting powders used in the US along with approx. percentage of total U.S. market. Refer to relationship with desired attributes.
- c. Particle size data on other cosmetic/USP/FCC talc products (brief).
- c. Discuss distinction between wet, dry, and airborne particle size distributions.
- d. Brief reference to talc used in NTP Study.

5. Quality Control

- a. Asbestos monitoring and testing.
- b. Typical process control and finished product testing protocols.
- c. Microbiological requirements and methods for control.

6. Summary

- a. Talc has been (and can be) used safely for cosmetic and comfort purposes.
- b. Reference to studies (to be discussed later in this symposium) that actual consumer exposure to dust generated during its use is very low.
- c. Close relationship of Talc Manufacturers with Cosmetic, Pharmaceutical, and Food Industries.

August 4, 1993

Richard Zasenski
Luzenac America Inc.
Manager Quality Assurance

Director-Toxicology

8/26

MIWA

This is the outline which
Rich Zaremski prepared. I think
this is exactly what FDA is looking
for. I talked to Don Hughes -
he agrees that this is where the
S&S exposure data should be used.

Can Fred Pooley handle this?
Is he "controllable"? Please call.

STW